02.05.2019 Issue 437

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Trump to Talk Health Costs During SOTU

Monday, February 4

Health care costs, namely prescription drug prices, are expected to be a key issue discussed during President Donald Trump’s second State of the Union address today, STAT reports.

Trump Administration Proposal Would End Pharma Rebates to PBMs

Trump’s Rebate Proposal Receives Mixed Reactions

HIMSS19 to Focus on Transparency, Data Exchange

New Paper Spotlights 2018 Trends in Specialty Drugs

Sachs Looks at Possible Implications of Rebates Proposal

Study: Payer Experts Say PIE Needs Legislative Safe Harbor

Reuters: CVS Adds Teva, Lilly Migraine Drugs

Anthem Bumps up Timeline for In-House PBM Launch

Survey: Americans Dissatisfied with Legislative Efforts on Drug Pricing


Head of Economic Modelling

Director, HEOR (Southeast)

Global Health Economics Senior Manager

Health Economics Senior Manager

Industry Spotlight


Conferences Webinars
Investigator Initiated Sponsored Research Summit
    February 6-7, Cambridge, Massachusetts

Paying for Cures: Ensuring Patient Access and System Sustainability
    February 12, Washington, D.C.

MRC training workshop on Health Economics Analysis Plans
    February 14, Bristol, England

18th Annual International Publication Planning Meeting
    February 20-21, San Diego, California

AMCP Policy and Advocacy Focus Areas for 2019
    February 5

Patient Engagement in Drug Development: An Opportunity for Medical Affairs
    February 6

Clinical Statistics for Non-Statisticians
    February 27

Amplifying the Patient Voice: Policy Solutions for Improving Patient-Reported Measures in Oncology Value-Based Payment Programs
    February 28


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
          Truven            
          Evidera    HealthCore    University of FL   Xcenda
      OM1    Parexel    Jefferson    Dymaxium   Precision Xtract    
      Pharmerit    eMax Health    Sciformix   Evidence Partners    ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn